KRAS and acute myeloid leukemia: We did not identify differences according to mutations in CEBPA, DNMT3A, KRAS/NRAS, IDH1, IDH2, ASXL1 and RUNX1. However, PPM1D expression was lower in FLT3-ITD AML compared with wt-cases (GSE6891, p = 0.017) and in NPM1-mut cases compared with wt-ones (GSE6891, p = 0.002).